Identification of prior dengue-naïve Dengvaxia recipients with an increased risk for symptomatic dengue during fever surveillance in the Philippines
IntroductionDengue virus (DENV) is the leading cause of mosquito-borne viral diseases in humans. Dengvaxia, the first licensed dengue vaccine, is recommended for DENV-seropositive individuals aged 9–45 years. In the Philippines, Dengvaxia was administered to more than 830,000 children without prior...
Main Authors: | Yu-Ching Dai, Ava Kristy Sy, Mario Jiz, Jih-Jin Tsai, Joan Bato, Mary Ann Quinoñes, Mary Anne Joy Reyes, Wei-Kung Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-07-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1202055/full |
Similar Items
-
A review of Dengvaxia®: development to deployment
by: Stephen J. Thomas, et al.
Published: (2019-10-01) -
Consider stopping dengvaxia administration without immunological screening
by: Maíra Aguiar, et al.
Published: (2017-04-01) -
Optimal Control of a Dengue-Dengvaxia Model: Comparison Between Vaccination and Vector Control
by: Mentuda Cheryl Q.
Published: (2021-11-01) -
REVIEW ARTICLE: DEVELOPEMENT AND USING DENGUE VACCINE FOR DENGUE INFECTION VIRUS
by: Firdaus Kabiru Massey, et al.
Published: (2019-08-01) -
Vaccine Hesitancy and the Cultural Politics of Trust in the Dengvaxia Controversy: A Critical Discourse-Ethnographic Study of Online News Content, Producers, and Audiences
by: Karl Patrick Mendoza
Published: (2020-12-01)